Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Zevra Denmark A/S manages a portfolio with 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct art units, suggesting a diverse range of pharmaceutical or biological innovations. The company is currently interacting with 3 distinct examiners for these matters.
JOHANSEN, PETER N. is the busiest examiner for this portfolio, with 1 pending office action currently under review. This means that each of the 3 distinct examiners is handling exactly one-third of the total 3 pending office actions. The use of 3 distinct art units indicates that the prosecution is not centralized in a single specialized group at the patent office.
Practitioners must coordinate strategies across 3 distinct examiners, which may lead to different timelines and requirements. Since each examiner, including JOHANSEN, PETER N., has only 1 pending office action, the workload is evenly spread. This distribution across 3 distinct art units requires a broad understanding of different examination practices within the Biotechnology & Pharmaceuticals field to ensure consistent results across the portfolio.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JOHANSEN, PETER N. | 1 | 59.3% | +24.4% |
| CORNET, JEAN P | 1 | 42.1% | +47.5% |
| SCHMITT, MICHAEL J | 1 | 56.8% | +20.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17059516 | HSP70 PROTEIN LEVELS IN PBMC SAMPLES AS BIOMARKER FOR DISEASE | JOHANSEN, PETER N. | 85d |
| 18267591 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | CORNET, JEAN P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17560549 | USE OF ARIMOCLOMOL IN THE TREATMENT OF NIEMANN PICK DISEASE | SCHMITT, MICHAEL J | 14d |
| 17059516 | HSP70 PROTEIN LEVELS IN PBMC SAMPLES AS BIOMARKER FOR DISEASE | JOHANSEN, PETER N. | 85d |
| 18267591 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | CORNET, JEAN P | — |
| Art Unit | Apps |
|---|---|
| 1644 | 1 |
| 1628 | 1 |
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17059516 | HSP70 PROTEIN LEVELS IN PBMC SAMPLES AS BIOMARKER FOR DISEASE | JOHANSEN, PETER N. | 1644 | §101§112 | Non-Final OA | 85d | Pending | Aug 01, 2023 |
| 18267591 | ARIMOCLOMOL FOR THE TREATMENT OF NIEMANN PICK DISEASE, TYPE C, IN PATIENTS WITH ER TYPE MISSENSE MUTATIONS | CORNET, JEAN P | 1628 | §102§103 | Non-Final OA | — | Pending | Jun 15, 2023 |
| 17560549 | USE OF ARIMOCLOMOL IN THE TREATMENT OF NIEMANN PICK DISEASE | SCHMITT, MICHAEL J | 1629 | §103DP | Non-Final OA | 14d | Pending | Dec 23, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial